UroGen Pharma Ownership | Who Owns UroGen Pharma?

Overview Forecast RevenueFinancials Chart Transcripts

UroGen Pharma Ownership Summary

UroGen Pharma is owned by 12.52% institutional investors, 3.64% insiders, and 83.84% retail investors. Rtw investments, lp is the largest institutional shareholder, holding 9.23% of URGN shares. BioPharma Credit Ord is the top mutual fund, with 10.18% of its assets in UroGen Pharma shares.

URGN Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	UroGen Pharma	12.52%	3.64%	83.84%
Sector	Healthcare Stocks	35.58%	11.87%	52.55%
Industry	Biotech Stocks	35.75%	11.83%	52.41%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Rtw investments, lp	4.54M	9.23%	$81.70M
Blackrock	2.19M	6.57%	$36.81M
Cowen and company	2.10M	6.29%	$35.23M
Blackrock funding, inc. /de	2.85M	5.78%	$51.16M
Toronto dominion bank	2.62M	5.32%	$47.05M
Morgan stanley	2.56M	5.20%	$46.03M
Kynam capital management, lp	2.25M	4.57%	$40.41M
Jefferies financial group	2.20M	4.47%	$39.55M
Paradigm biocapital advisors lp	1.70M	3.46%	$30.64M
Acorn capital advisors	1.67M	3.40%	$30.09M

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Acorn capital advisors	1.67M	8.55%	$30.09M
Superstring capital management lp	387.37K	4.98%	$6.96M
Opaleye management	1.43M	3.39%	$25.71M
Silverarc capital management	1.50M	2.76%	$27.02M
Kynam capital management, lp	2.25M	2.49%	$40.41M
Bioimpact capital	943.80K	1.31%	$16.97M
Boxer capital management	500.00K	1.18%	$8.99M
Cowen and company	2.10M	0.97%	$35.23M
Privium fund management b.v.	238.12K	0.89%	$4.28M
Rtw investments, lp	4.54M	0.81%	$81.70M

Top Buyers

Holder	Shares	% Assets	Change
Toronto dominion bank	2.62M	0.07%	2.62M
Kynam capital management, lp	2.25M	2.49%	2.25M
Opaleye management	1.43M	3.39%	1.16M
Soleus capital management	727.00K	0.53%	577.00K
Frontier capital management	1.31M	0.24%	532.49K

Top Sellers

Holder	Shares	% Assets	Change
Ra capital management	-	-	-3.21M
Paradigm biocapital advisors lp	1.70M	0.63%	-2.77M
Adage capital partners gp	-	-	-830.00K
Healthcare of ontario pension plan trust fund	387.07K	0.01%	-738.03K
Price t rowe associates inc /md/	28.45K	0.00%	-588.15K

New Positions

Holder	Shares	% Assets	Change	Value
Vestal point capital, lp	139.08K	0.07%	139.08K	$2.50M
Two sigma advisers, lp	111.60K	0.00%	111.60K	$2.23M
Swiss national bank	77.80K	0.00%	77.80K	$1.40M
State of wisconsin investment board	32.12K	0.00%	32.12K	$577.45K
Vanguard fiduciary trust	31.56K	0.00%	31.56K	$567.43K

Sold Out

Holder	Change
Nelson, van denburg & campbell wealth management group	-4.00
Clearstead advisors	-9.00
Srs capital advisors	-14.00
Us bancorp \de\	-17.00
Coldstream capital management	-29.00

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Mar 31, 2026	70	-60.00%	6,164,059	-85.90%	12	0.15%	34	-57.50%	15	-72.73%
Dec 31, 2025	99	-42.11%	18,257,389	-58.48%	37	0.45%	43	-49.41%	32	-30.43%
Sep 30, 2025	162	4.52%	41,959,889	15.94%	87	1.53%	82	2.50%	45	7.14%
Jun 30, 2025	163	13.99%	39,787,671	-4.46%	83	1.08%	84	31.25%	43	-12.24%
Mar 31, 2025	143	2.14%	41,643,982	14.80%	87	1.24%	64	-11.11%	49	25.64%

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
BioPharma Credit Ord	4.69M	10.18%	4.69M
RTW Biotech Opportunities Ord	1.36M	2.90%	1.36M
UBS (Lux) Digital Health Equity SB USD	1.32M	2.86%	-
UBS Lux Dgtl Hlth Eq Fd seeding P acc	1.25M	2.71%	-
iShares Russell 2000 ETF	949.88K	1.95%	7.99K
American Century Small Cap Growth Inv	874.98K	1.80%	221.94K
American Century U.S. Small Cap Growth	874.98K	1.80%	221.94K
Biotech Growth Ord	536.83K	1.10%	-
International Biotechnology Ord	427.15K	0.93%	-34.85K
Fidelity Small Cap Index	360.64K	0.74%	3.68K

Recent Insider Transactions

Date	Name	Role	Activity	Value
Jun 08, 2026	Schoenberg Mark	Chief Medical Officer	Sell	$142.56K
May 08, 2026	Schoenberg Mark	Chief Medical Officer	Sell	$300.00K
Feb 03, 2026	Smith Jason Drew	General Counsel	Sell	$63.34K
Feb 03, 2026	Smith Jason Drew	General Counsel	Sell	$52.26K
Feb 03, 2026	Smith Jason Drew	General Counsel	Sell	$31.66K

Insider Transactions Trends

Date	Buy	Sell
2026 Q2	-	2
2026 Q1	-	6
2025 Q4	-	2
2025 Q3	-	5
2025 Q2	-	1

URGN Ownership FAQ

Who Owns UroGen Pharma?

UroGen Pharma shareholders are primarily institutional investors at 12.52%, followed by 3.64% insiders and 83.84% retail investors. The average institutional ownership in UroGen Pharma's industry, Biotech Stocks , is 35.75%, which UroGen Pharma falls below.

Who owns the most shares of UroGen Pharma?

UroGen Pharma’s largest shareholders are Rtw investments, lp (4.54M shares, 9.23%), Blackrock (2.19M shares, 6.57%), and Cowen and company (2.1M shares, 6.29%). Together, they hold 22.09% of UroGen Pharma’s total shares outstanding.

Does Blackrock own UroGen Pharma?

Yes, BlackRock owns 6.57% of UroGen Pharma, totaling 2.19M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 36.81M$. In the last quarter, BlackRock increased its holdings by 477.14K shares, a 27.79% change.

Who is UroGen Pharma’s biggest shareholder by percentage of total assets invested?

Acorn capital advisors is UroGen Pharma’s biggest shareholder by percentage of total assets invested, with 8.55% of its assets in 1.67M UroGen Pharma shares, valued at 30.09M$.

Who is the top mutual fund holder of UroGen Pharma shares?

BioPharma Credit Ord is the top mutual fund holder of UroGen Pharma shares, with 10.18% of its total shares outstanding invested in 4.69M UroGen Pharma shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools